Massachusetts now licenses and regulates PBMs under M.G.L. c. 176Y (created by Chapter 342 of the Acts of 2024), with licensure required by January 1, 2026. PBMs must keep MAC pricing current — updated at least every 7 days — offer a MAC appeal, report cost and pricing data, and observe consumer cost-sharing caps on certain drugs.
The law does not, however, set a NADAC or acquisition-cost reimbursement floor, and notably it does not ban spread pricing (it requires disclosure of the practice instead). It is therefore a licensure-and-transparency regime rather than a floor.